biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > After 14 years, GET AN IND SUBMISSION IN TO THE FDA!!

<< Previous

Bullboard Posts

Next >>

Comment by KayakerBCon Apr 06, 2022 12:47pm

92 Views

Post# 34581047

RE:RE:RE:RE:After 14 years, GET AN IND SUBMISSION IN TO THE FDA!!

....If there is no mention of an extention of the Daiichi agreement by the time of the next financials or that they have completed their objective and are evaluating the path forward or have received more funding from Daiichi for an extention, etc., it is not a basis to assume a rosy outcome....

Neither is it a basis for assuming a bad outcome. We could hear soon or it simply may require more time.

Your focus on expecting some kind of quick announcement looks suspicious to me. Are you trying to set this up as an opportunity to spread some FUD?

(my bolding)

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week